Anti-Infectives 2009

Ceftobiprole  

• Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009; 34(1): 1-7.
  
• Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D, Murthy B, Derendorf H. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother. 2009; 53(7): 2773-2776.
• Barton E, MacGowan A. Future treatment options for Gram-positive infections - looking ahead. Clin Microbiol Infect. 2009; 15(SUPPL.6): 17-25.
  
• Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM, Bush K. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53(7): 2785-2790.
• Bazan JA, Martin SI, Kaye KM. Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime. Infect Dis Clin North Am. 2009; 23(4): 983-996.
• Borbone S, Campanile F, Bongiorno D, Jeddari S, Scuderi C, Stefani S. In vitro activity of ceftobiprole against a group of well-characterised staphylococci. Clin Microbiol Infect. 2009; 15: S294.
  
• Cornaglia G, Rossolini GM. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect. 2009; 15(3): 218-223.
• Corvec S, Cremet L, Lepelletier D, Reynaud A, Drugeon H. Overproduction of K1 enzyme in Klebsiella oxytoca clinical isolates against ceftazidime, cefepime and ceftobiprole. J Chemother. 2009; 21(3): 365-366.
• Davies TA, Shang W, Amsler KM, Bajaksouzian S, Jacobs MR, Bush K. Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials. Int J Antimicrob Agents. 2009; 34(2): 166-168.
• Decorby M, Weshnoweski B, Vashisht R, Tailor F, Turner-Brannen E, McCracken M, Mulvey M, Karlowsky J, Lagacé-Wiens P, Walkty A, Hoban D, Zhanel G. Antimicrobial resistance in pathogens isolated from Canadian hospital Clinics (C), Emergency Rooms (ER), medical/surgical Wards (W) and Intensive Care Units (ICU): Results of the CANWARD 2008 study. Int J Antimicrob Agents. 2009; 34: S48.
  
• El Solh AA. Ceftobiprole: A new broad spectrum cephalosporin. Expert Opin Pharmacother. 2009; 10(10): 1675-1686.  
  
• Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Miró JM, Cercenado E, Domínguez MDLA, Soriano Á, Rodríguez-Baño J, Vallés J, Palomar M, Tornos P, Bouza E. Concensus document for the treatment of bacteremia and endicarditis caused by methicillin-resistant Staphylococcus aureus. Enferm Infecc Microbiol Clin. 2009; 27(2): 105-115.
• Gysling E. Ceftobiprole. Pharma-Krit. 2009; 31(13): 50-51.
  
• Hanssen H-P. From research: New broad spectrum cephalosporin ceftobiprole. Dtsch Apoth Ztg. 2009; 149(41): 49.
  
• Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Anti-Infect Drug Discov. 2009; 4(1): 57-65.
• Hellmark B, Unemo M, Nilsdotter-Augustinsson Å, Söderquist B. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect. 2009; 15(3): 238-244.
• Hoban D, Decorby M, Weshnoweski B, Vashisht R, Tailor F, Karlowsky J, Zhanel G. Evaluation of the activity of ceftobiprole and doripenem against common clinical pathogens obtained from Canadian hospital wards using Etest methodology. Int J Antimicrob Agents. 2009; 34: S56.
  
• Jones R, Sader H, Janechek M, Rhomberg P. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant S. aureus cephalosporin, tested against skin and skin-structure infection pathogens (North America). Clin Microbiol Infect. 2009; 15: S293-294.  
• Kimko H, Murthy B, Xu X, Nandy P, Strauss R, Noel GJ. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009; 53(3): 1228-1230.
  
• Kimko H, Xu X, Nandy P, Samtani MN, Strauss RS, Bagchi P, Noel GJ. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009; 53(8): 3371-3374.
• Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009; 11(4): 282-286.
  
• Kresken M, Höffken G, Shah PM. Parenteral cephalosporins, reasons for a new group. Chemother J. 2009; 18(4): 142-144.
• Lemaire S, Glupczynski Y, Duval V, Joris B, Tulkens PM, Van Bambeke F. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009; 53(6): 2289-2297.
• Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009; 64(Suppl 1): i29-36.
• Lu JJ, Hsueh PR, Lee SY. Clonal dissemination of vancomycin-intermediate and methicillin-resistant Staphylococcus aureus in Taiwan. Clin Microbiol Infect. 2009; 15:  S10.
  
• Marti S, Sánchez-Céspedes J, Espinal P, Vila J. In vitro activity of ceftobiprole against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents. 2009; 34(3): 265-267.
• Mlynarczyk A, Mlynarczyk B, Kmera-Muszynska M, Majewski S, Mlynarczyk G. Mechanisms of the resistance and tolerance to beta-lactam and glycopeptide antibiotics in pathogenic gram-positive cocci. Mini-Rev Med Chem. 2009; 9(13): 1527-1537.
• Neuner EA, Ritchie DJ, Micek ST. New antibiotics for healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009; 30(1): 92-101.
• Ohlsen K. Novel antibiotics for the treatment of Staphylococcus aureus. Expert Rev Clin Pharmacol. 2009; 2(6): 661-672.  
• Page MGP, Heim J. New molecules from old classes: Revisiting the development of β-lactams. Idrugs. 2009; 12(9): 561-565.

• Patel SN, Pillai DR, Pong-Porter S, Mcgeer A, Green K, Low DE. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother. 2009; 64(3): 659-660.

• Peppard WJ, Daniels A, Fehrenbacher L, Winner J. Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus. Infect Drug Resist. 2009; 2(1): 27-40.
  
• Reygaert W. Methicillin-resistant Staphylococcus aureus (MRSA): identification and susceptibility testing techniques. Clin Lab Sci. 2009; 22(2): 120-124.
• Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob. Agents Chemother. 2009; 53(8): 3294-3301.
• Sader H, Rhomberg P, Janechek M, Jones R. Spectrum and potency of ceftobiprole against leading North American pathogens producing community- and hospital-acquired pneumonia (2005-2007). Clin Microbiol Infect. 2009; 15: S293.
  
• Schirmer PL, Deresinski SC. Ceftobiprole: A new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti-Infect Ther. 2009; 7(7): 777-791.
• Schmitz FJ, Perry J, Zbinden R, Quintana A, Laeuffer J, Cassettari ML, Morrissey I. Comparative susceptibility of European Gram-positive pathogens to ceftobiprole, vancomycin, teicoplanin and linezolid. Clin Microbiol Infect. 2009; 15: S464-S465.
• Seifert H, Dryden M, Quintana A, Laeuffer J, Okolo P, Morrissey I. Comparative susceptibility of European Gram-negative pathogens to ceftobiprole, ceftazidime and cefepime. Clin Microbiol Infect. 2009; 15: S273.  
  
• Shah PM, Kresken M, Höffken G. Suggestion for a new classification of parenteral cephalosporins. Chemother J. 2009; 18(4): 145-146.
  
• Shahid M, Sobia F, Singh A, Malik A, Khan HM, Jonas D, Hawkey PM. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Crit Rev Microbiol. 2009; 35(2): 81-108.
• Solomkin JS, Noel GJ, Strauss R. A scoring system to predict outcomes in complicated skin and skin structure infections derived from phase III studies of ceftobiprole. Surg Infect. 2009; 10(2): 210.
  
• Sorlozano A, Carrasco C, Cabeza J, Villegas E, Gutierrez J. Antimicrobial development in the era of emerging resistance. Mini-Rev Med Chem. 2009; 9(8): 938-955.
• Stefani S. Evolution in the antibiotic susceptibility and resistance. Infez Med. 2009; 17 (Suppl 3): 5-12.
  
• Stein RA, Goetz RM, Ganea GM. Ceftobiprole: A new β-lactam antibiotic. Int J Clin Pract. 2009; 63(6): 930-943.
  
• Stevens DL. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect. 2009; 59(Suppl 1): S32-S39.
• Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care. 2009; 15(5): 403-412.
  
• Vidaillac C, Rybak MJ. Ceftobiprole: First cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Pharmacotherapy. 2009; 29(5):  511-525.

• Yang QW, Wang H, Sun HL, Xu YC, Xie XL, Chen MJ. In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection. Zhonghua Nei Ke Za Zhi. 2009; 48(3): 220-224.

• Zelenitsky S, Ariano R, Zhanel G. Selecting the best empirical therapy for patients in Canadian intensive care units. Can J Hosp Pharm. 2009; 62(4): 340.
• Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother. 2009; 64(2): 364-369.
  

• P-1033 / Comparative susceptibility of European Gram-negative pathogens to ceftobiprole, ceftazidime and cefepime. Seifert H, Dryden M, Quintana A, Laeuffer J, Okolo P, Morrissey I.
• P-1095 / Spectrum and potency of ceftobiprole against leading North American pathogens producing community- and hospital-acquired pneumonia (2005-2007). Sader H, Rhomberg P, Janechek M, Jones R. 
• P-1096 / Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant S. aureus cephalosporin, tested against skin and skin-structure infection pathogens (North America). Jones R, Sader H, Janechek M, Rhomberg P. 
• P-1097 / In vitro activity of ceftobiprole against a group of well-characterized staphylococci. Borbone S, Campanile F, Bongiorno D, Jeddari S, Scuderi C, Stefani S.
• P-1633 / Comparative susceptibility of European Gram-positive pathogens to ceftobiprole, vancomycin, teicoplanin and linezolid. Schmitz FJ, Perry J, Zbinden R, Quintana A, Laeuffer J, Cassettari ML, Morrissey I.
     
  
   

Isavuconazole

• Bretagne S. Are there new antifungal molecules? Antibiotiques. 2009; 11(3): 133-141.
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: Mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti-Infect Ther. 2009; 7(8): 981-998.
  
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Invest Drugs. 2009; 18(9): 1279-1295.
• González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009; 47(1): 71-76.
• Hope W. PK/PD and azoles. Clin Microbiol Infect. 2009; 15: S42.
• Kouranos VD, Karageorgopoulos DE, Peppas G, Falagas ME. Comparison of adverse events between oral and intravenous formulations of antimicrobial agents: A systematic review of the evidence from randomized trials. Pharmacoepidemiol Drug Saf. 2009; 18(10): 873-879.  
  
• Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother. 2009; 63(1): 161-166.
• Pelaíez T, Guinea J, Gama B, Flores R, Recio S, Torres-Narbona M, Muñoz P, Bouza E. Is Aspergillus nidulans susceptible to all antifungal agents? In vitro activity of an updated panel of antifungal agents against 63 clinical isolates. Clin Microbiol Infect. 2009; 15: S358.
  
• Perkhofer S, Lechner V, Lass-Flörl C. In vitro activity of isavuconazole against aspergillus species and zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother. 2009; 53(4): 1645-1647.
• Schmitt-Hoffmann AH, Roos B, Peterfai E, Edwards D, Spickermann J, Heep M. Oral pharmacokinetics of isavuconazole in liver impairment due to cirrhosis. Clin Microbiol Infect. 2009; 15: S475.
  
• Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfaí É, Edwards DJ, Stoeckel K. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009; 53(11): 4885-4890.
  
• Taj-Aldeen SJ, Al-Ansari N, El Shafei S, Meis JF, Curfs-Breuker I, Theelen B, Boekhout T. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: Isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol. 2009; 47(6): 1791-1799.
  
• Thompson III GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.  Antimicrob Agents Chemother. 2009; 53(1): 309-311.
• Thompson III GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009; 64(1): 79-83.
• Verweij P, Gonzalez G, Wiederhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J. In vitro antifungal activity of isavuconazole against 345 mucorales isolates, collected at eight study centres worldwide. Clin Microbiol Infect. 2009; 15: S358-S359.
  
• Verweij PE , González GM, Wiederhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother. 2009; 21(3): 272-281.
• Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: Mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009; 53(8): 3453-3461.

49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, September 2009, San Francisco, United States of America

• P-1297 / Is Aspergillus nidulans susceptible to all antifungal agents? In vitro activity of an updated panel of antifungal agents against 63 clinical isolates. Peláez T, Guinea J, Gama B, Flores R, Recio S, Torres-Narbona M, Muñoz P, Bouza E.
• P-1298 / In vitro antifungal activity of isavuconazole against 345 mucorales isolates, collected at eight study centers worldwide. Verweij P, Gonzalez G, Wiederhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J.
• P-1665 / Oral pharmacokinetics of isavuconazole in liver impairment due to cirrhosis. Schmitt-Hoffmann AH, Roos B, Peterfai E, Edwards D, Spickermann J, Heep M.   

Research

International conference on Molecular Targets and Cancer Therapeutics, November 2009, Boston, United States of America

• C-229 / BAL27862: A novel anticancer agent that dissociates microtubules and creates a distinct cellular phenotype. Bachmann F, Burger K, Pohlmann J, Kellenberger L, Lane H.  
• C-233 / BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors. Schmitt-Hoffmann A, Klauer D, Gebhardt K, Brendle A, Fullhardt P, Hargreaves P, Bucher C, Schläfle C, Spickermann J, Defoin R, Burger K, Vuong V, Pruschy M, Bachmann F, Lane H.
  

49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC,September 2009, San Francisco, United States of America

• F1-1478 / In vitro activity of BAL30072 against Burkholderia pseudomallei. Mima T, Page MGP, Desarbre E, Schweizer HP. 
• F1-1479 / Synergy between the siderophore monobactam BAL30072 and carbapenems investigated by time-kill and checkerboard studies. Page MGP, Desarbre E, Müller C, Hofer B. 
• F1-1480 / Interactions between the siderophore monobactam BAL30072 and carbapenems provides a powerful combination for addressing multi-resistant organisms. Page MGP, Desarbre E, Müller C, Hofer B, Dantier C. 
• F1-1481 / In Vitro Potency of a Siderophore Monobactam BAL30072 (BAL) Against Gram Negative Bacilli (GNB) with Defined β-lactamase Enzymes. Bowker KE, Noel AR, Walsh TR,  MacGowan AP. 
• F1-1482 / Meropenem (MEM) and BAL30072, a unique carbapenem-siderophore monobactam combination with extended activity against multidrug (MDR) resistant Acinetobacter baumannii. Hujer AM, Hujer KM, Desarbre E, Page MGP, Bonomo RA.
• F1‑1483 / In vivo Gram-negative Activity of BAL30072 in a Mouse Septicemia Model. Schmitt-Hoffmann A, Gebhardt K, Brendle A, Fullhardt P, Klauer D, Hofer C, Müller M, Page MGP.
• F1-1484 / Antibacterial activity of BAL30072, a siderophore monobactam antibiotic, against E. coli in experimental urinary tract infection in mice. Andersen JM, Lundgren CV, Page MGP, Frimodt-Møller N. 
• F1-1485 / Efficacy of BAL30072 in Experimental Respiratory Tract Infections. Weiss WJ, Pulse ME, Nguyen P, Pierce J, Simecka J, Page MGP.
• F1‑1486 / BAL30072 is active against Acinetobacter baumannii in a rat soft-tissue infection model. Russo TA, Page MGP, Beanan J, Olson R, Hujer AM, Hujer KM, Endimiani A, Bonomo RA.

19th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, May 2009, Helsinki, Finland

• P-1110 / Resistance Development Studies with the Novel Siderophore Monobactam BAL30072. Page M, Mueller C, Hofer B, Desarbre E. 
• P-1111 / Bactericidal Effect of the Novel Siderophore Monobactam BAL30072. Page M, Mueller C, Hofer B, Desarbre E.
• P-1112 / In vitro Activity of a New Siderophore Monobactam BAL30072 Against ESBL Producing Enterobateriacae and Clinical Isolates of Enterobacter cloacae. Bowker KE, Walsh TR, MacGowan AP.